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S U M M A R Y
The Western Paciﬁc Regional Green Light Committee (rGLC WPR) was established in 2011 to promote the
rational scale-up of programmatic management of drug-resistant tuberculosis (PMDT). We reﬂect on its
achievements, consider the challenges faced, and explore its potential future role. Achievements include
the supervision and support of national PMDT action plans, increased local ownership, contextualized
guidance, and a strong focus on regional capacity building, as well as a greater awareness of regional
challenges. Future rGLC activities should include (1) advocacy for high-level political commitment; (2)
monitoring, evaluation, and supervision; (3) technical support and contextualized guidance; and (4)
training, capacity building, and operational research. Regional activities require close collaboration with
both national and global efforts, and should be an important component of the new Global Drug-
resistant TB Initiative.
 2015 T. Islam. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Multidrug-resistant tuberculosis (MDR-TB; cases infected with
Mycobacterium tuberculosis that is resistant to isoniazid and
rifampicin) is a major threat to global gains in TB control. The
management of MDR-TB is more difﬁcult than that of drug-
susceptible TB. It requires specialized laboratory diagnostics, a
long duration of treatment with expensive and toxic drugs, careful
monitoring of treatment progress, and addressing frequent
adverse drug reactions. Programmatic management of drug-
resistant TB (PMDT) requires considered planning and adequate
and well-trained human resources, together with strong political
commitment for institutional support and funding security.* Corresponding author. Tel.: +(632) 528 9720; fax: +(632) 521 1036.
E-mail address: islamt@wpro.who.int (T. Islam).
http://dx.doi.org/10.1016/j.ijid.2015.01.001
1201-9712/ 2015 T. Islam. Published by Elsevier Ltd on behalf of International Society f
(http://creativecommons.org/licenses/by-nc-nd/4.0/).The original Green Light Committee (GLC) was formed in 2000 to
provide technical assistance to DOTS (the internationally recom-
mended strategy for TB control) programmes and to promote the
rational use of and improve access to concessionally priced, quality-
assured, second-line anti-TB drugs.1 The GLC assisted many
countries in setting up pilot PMDT projects and established the
principles for responsible MDR-TB management in resource-limited
settings. Best practice guidelines detailing the choice of regimens
were published in 1996 to guide clinicians on TB treatment, but the
ﬁrst guidelines on PMDT were published by the World Health
Organization (WHO) in 2006, and included experiences from
different GLC projects.1 In 2009, a ministerial meeting in Beijing
of 27 countries with a high burden of MDR-TB called for urgent
action to reduce the imminent threat of the emergence and spread of
drug-resistant TB.2 World Health Assembly resolution WHA
62.15 focused on the prevention and control of drug-resistant TB,
and was approved by the Sixty-second World Health Assembly inor Infectious Diseases. This is an open access article under the CC BY-NC-ND license
Figure 1. Structure of the Western Paciﬁc Regional Green Light Committee (rGLC
WPR).
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and adequate funding allocation, together with the development of
global, regional, and national action plans.3
A revised global framework to support PMDT was developed in
2010. The framework recognized the need to improve access to
diagnosis and treatment, and to limit the transmission of drug-
resistant TB. It called for the establishment of decentralized
regional structures to enhance country engagement, oversight, and
support.4 In 2011, the Western Paciﬁc Region Green Light
Committee (rGLC WPR) was established to assist member
countries with rational scaling up of PMDT. The rGLC WPR was
mandated to provide inputs to national strategies/action plans for
PMDT scale-up, oversee the provision of technical assistance to
countries, review monitoring mission reports and surveillance
data, improve access to and rational use of quality-approved
medicines, and promote advocacy for regional PMDT scale-up. We
provide a brief overview of rGLC WPR activities, reﬂect on its
achievements and challenges, and explore its potential future role.
2. Structure of the rGLC
The rGLC initiative shifted the focus from ‘regulation and
control’ to ‘support and assistance’, with a strong emphasis on
regional ownership, increased involvement of country represen-
tatives, and local capacity building. Member countries were at
different stages of PMDT implementation with consequent diverse
needs, ranging from the Philippines with the earliest GLC-
approved programme5 to settings without any PMDT experience.
An rGLC secretariat was established at the WHO Regional Ofﬁce
for the Western Paciﬁc in Manila, and an expert committee
contributing the following skill sets was convened: development
and review of PMDT scale-up plans; clinicians with experience in
managing drug-resistant TB, including paediatric and HIV-infected
patients; patient support, nursing care, and case-holding strate-
gies; drug management; laboratory aspects; infection control;
epidemiology and surveillance and information systems; and
communication and advocacy. A call for applications was made for
the selection of individuals to serve as members on the rGLC WPR
for a period of 2 years. Interested applicants were asked to respond
with a motivation letter, a copy of their curriculum vitae, and a
covering letter emphasizing their relevant MDR-TB experience,
speciﬁc technical expertise, and the constituency to be repre-
sented. The selection was made by a committee comprising the
Stop TB Partnership (STP), the MDR-TB working group of the STP,
and the WHO. The selection was based on clear criteria, which
included a rational distribution of areas of expertise and
experience, previous GLC experience, geographical and gender
distribution, and constituency represented. Preference was given
to applicants from and/or with extensive experience in the
Western Paciﬁc Region. Members were selected for an initial
2-year term, with provision for at least half of the members to
secure a second term in order to ensure continuity.
The rGLC mechanism is not only an expert committee, but a
partnership of the Committee, countries, technical organizations, and
donor agencies (Figure 1). The Committee performs an overseer role
and the Secretariat ensures coordination. The mechanism encourages
countries to share their experiences and taps into the expertise of
various technical organizations for speciﬁc technical assistance to the
country as relevant. Donor agencies provide funding support for
scaling up PMDT and receive updated status information on
programme implementation through the mechanism.
3. Size of the challenge and key activities
Globally in 2013, a total of 300 000 (range 230 000–380 000)
among notiﬁed TB cases were estimated to have MDR-TB,6 withnearly one quarter (71 000, 95% conﬁdence interval (CI) 47 000–
94 000) of them in countries of the WHO Western Paciﬁc Region.
The Region includes countries with high MDR-TB case-loads, such
as China, Viet Nam, and the Philippines, and remote Paciﬁc Island
nations with very small and irregular case-loads.7 Table 1
summarizes the estimated MDR-TB case-numbers in the countries
of the Western Paciﬁc Region.
Key activities of the rGLC WPR have included assistance with
the formulation of national PMDT action plans, PMDT programme
evaluation, critical review of mission reports, establishing and
administering a quality-assured second-line drug repository for
small Paciﬁc Island nations, and contributions to regional capacity
building with ongoing strategic and technical guidance. Technical
support has included all aspects of programme performance, with
particular emphasis on quality assurance of laboratory protocols,
treatment, and case management.
The expert committee has had regular teleconferences and bi-
annual face-to-face meetings. Meetings have been arranged to
coincide with regional TB events, which has minimized costs and
allowed rGLC members to interact with country programme
managers, raise awareness of MDR-TB, and provide expert advice.
These interactions have increased mutual understanding of both
country and regional TB control challenges, and have provided
opportunities for addressing these challenges.
The Secretariat has coordinated monitoring missions to all
countries with a high MDR-TB burden and has arranged critical
reviews of country reports within strict timelines. Priority
recommendations have been clearly communicated and progress
reviewed during subsequent visits. In addition to the routine
monitoring missions, special technical assistance missions have
been arranged to address country-speciﬁc challenges, such as
clinical audit tools, pharmacovigilance, protocol development for
the management of extensively drug-resistant TB (XDR-TB; MDR
with additional resistance to ﬂuoroquinolones and one or more of
the second-line injectable agents), etc. Regional training of trainers
and consultant courses on PMDT and drug management have been
organized, as well as in-country training on the clinical aspects of
MDR-TB management.
A workshop exploring pragmatic ways of strengthening and
harmonizing the regulation of TB medicines in the Region has
taken place, involving national TB programmes (NTPs), national
medicine regulatory authorities (NMRAs), technical partners, and
other key stakeholders. This workshop served as an entry point for
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medicines in the Western Paciﬁc Region. Clinical consultation on
MDR-TB case management has been provided for Paciﬁc Island
countries and areas, and a rotating stockpile of second-line anti-TB
drugs maintained for their use. To address programmatic
problems, seek alternative approaches, and improve programme
performance, the Secretariat has been involved in various
operational research projects in collaboration with NTPs and other
stakeholders. Recognizing the important role of the private sector
within the Region, the Secretariat has developed a ‘private sector
assessment tool’ and has piloted the tool. rGLC has also worked
with governments on the introduction and protection of novel TB
drugs.8
4. Achievements
An important outcome of decentralization of the GLC has been
the development of a regional pool of experts for PMDT support
and scale-up. Their involvement has increased regional capacity,
reduced mission expenses, and improved the feasibility of
recommendations. It has stimulated greater local ownership of
the MDR-TB problem, encouraging countries to critically assess the
performance of all PMDT activities, irrespective of Global Fund
support or GLC approval. Regional analysis of the drug resistance
TB situation has been performed to assist all stakeholders to
understand the situation better.7 Assessment of GLC-approved and
non-approved programmes has demonstrated that non-approved
programmes fare much worse, but has also emphasized the unmet
patient demand and the need for private sector engagement. The
analysis of the procurement and sales data of anti-TB drugs from
both the public and private sectors in the Philippines has shown
that an enormous quantity of anti-TB drugs have been channelled
through the private market outside the purview of the NTP.9 The
analysis of private sector contributions to PMDT in the Philippines
has facilitated the agenda for responsible private sector involve-
ment.10
PMDT should not be a stand-alone programme. The siloing of
PMDT activities has been a major barrier to enhanced local
oversight, ownership, and responsible programme expansion.
PMDT should be part and parcel of routine TB programme activities
and part of the overall health-care system. The rGLC WPR has
advocated for and encouraged integration of the PMDT with overall
TB control activities by organizing rGLC meetings with other TB-
related events, participating in joint programme reviews, and
coordination with other sectors such as NMRAs, maternal and child
health programmes, paediatricians, and others.Table 1
Estimated numbers of MDR-TB cases among notiﬁed pulmonary TB cases in countries 
MDR-TB among new TB cases 
n (95% CI) % 
China 45 000 (35 000–55 000) 6 
Philippines 4400 (3100–6000) 2 
Viet Nam 3000 (1900–4100) 4 
Republic of Korea 780 (600–980) 3 
Papua New Guinea 560 (340–800) 5 
Cambodia 320 (160–580) 1 
Mongolia 33 (16–59) 1 
Lao People’s Democratic Republic 160 (96–230) 5 
Japan 110 (63–160) <1 
Western Paciﬁc Region 53 000 (31 000–75 000) 4 
CI, conﬁdence interval; MDR-TB, multidrug-resistant tuberculosis.
a Source: Global TB database (http://www.who.int/tb/country/data/download/en/).
b Restricted to those with a case-load of more than 50 patients.Oversight by the rGLC WPR has ensured optimal value
extraction from country missions. All reports have been critically
reviewed with clear formulation of feasible and prioritized
recommendations. Challenges and bottlenecks have varied accord-
ing to the different stages of PMDT implementation, requiring
different types of technical assistance (Figure 2). The rGLC has
beneﬁted from the existing close relationships between the WHO
Regional Ofﬁce and member countries, which has enhanced the
articulation of local priorities and needs. The decentralized rGLC
model has been found to be more accessible and has created a
platform for sharing experiences (both frustrations and successes),
strengthening local ownership and encouraging innovative local
solutions. Enrolment statistics since 2011 conﬁrm that an
increasing number of patients have accessed care (Table 2), despite
major ﬁnancial constraints.11 The rising trend demonstrates the
readiness for PMDT scale-up, and the credit for the progress made
belongs to the respective countries. However, considerable unmet
needs remain.
5. Challenges
Although local ownership at the TB programme level has
improved, national prioritization remains low and the domestic
resources allocated to PMDT are grossly inadequate. In 2013, of the
expenditure on PMDT in the countries in the WHO Western Paciﬁc
Region, 18.4% was from domestic sources, with the remaining
81.6% from external grants.7 The gap between the estimated
number of MDR-TB patients and those receiving adequate care
grows wider. Despite a steady increase in PMDT enrolment, cases
treated in 2013 represented only16% of all estimated MDR-TB
cases among notiﬁed pulmonary TB cases.6,7 Without greatly
increased domestic investment, the long-term sustainability of
donor-funded programmes is a serious concern. Major funding
shortfalls demonstrate the need for greatly increased advocacy and
strong regional political commitment to contain the spread of
MDR-TB. High- and middle-income countries need to increase
domestic resources. Innovative health ﬁnancing (health insurance,
social protection schemes, etc.) may play an important role.
However, it is to be noted that considerable donor support will still
need to be continued for low-income countries.
Among the total estimated number of MDR-TB cases, 25%
(18 000, 95% CI 15 000–21 000) are among retreatment cases and
75% (53 000, 95% CI 47 000–75 000) among new TB cases,7 posing a
major challenge to enhanced case detection. Due to limited
funding, MDR-TB detection in many countries is focused
exclusively on retreatment cases, or even those failing the
retreatment regimen, since these groups have the highestof the Western Paciﬁc Regiona,b
MDR-TB among previously treated TB
cases
Total MDR-TB cases
n (95% CI) % n (95% CI)
9200 (7800–11 000) 26 54 000 (48 000–61 000)
4100 (3000–5500) 21 8500 (6900–10 000)
2100 (1500–2600) 23 5100 (4100–6100)
1200 (850–1600) 14 1900 (1600–2300)
570 (480–650) 24 1100 (890–1400)
180 (68–370) 11 510 (270–740)
210 (180–240) 34 240 (210–280)
65 (56–75) 24 220 (160–290)
100 (72–130) 10 200 (150–260)
18 000 (15 000–21 000) 22 71 000 (47 000–94 000)
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Figure 2. Thematic diagram of technical support requirements during different phases of PMDT scale-up.
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MDR-TB burden is occurring among new cases and this trend is
likely to increase if ongoing transmission of MDR-TB is not
contained. Broadening the presumptive MDR-TB criteria to
include all new cases has substantial funding implications. The
development of rapid diagnostic tools is paving the way for a rapid
increase in the number of diagnosed MDR-TB patients, but those
diagnostic tools need to be used properly—different diagnostic
algorithms will have different impacts in different country
settings. Health economic evaluation (such as cost-effectiveness
analysis) of different models will help countries to choose the best
model for themselves. Countries need to be pragmatic and tailor
their responses to the local epidemic and available resources.
Poor treatment outcomes of MDR-TB cases remain a major
concern. Treatment success for the 2011 cohort was only 52% in the
Region.7 Although comparable to the global average (48%),6 better
outcomes are required and can be achieved. Achieving optimal
outcomes is essential to retain enthusiasm for PMDT expansion,
and for patients, their communities, and governments to retain
faith in the value of this important public health programme. Low
success rates may be a consequence of transitioning from pilot
projects to nationwide expansion, with high loss to follow-up. This
poses a serious risk of amplifying drug resistance, and theTable 2
Yearly enrolment into programmatic management MDR-TB (PMDT) programmes in
the Western Paciﬁc Regiona,b
Country Year
2010 2011 2012 2013
Cambodia 38 57 110 121
China 1222 1155 1906 2184
Laos 2 2 9 4
Mongolia 156 126 171 192
Philippines 548 2397 1918 2262
Papua New Guinea 0 60 82 145
Viet Nam 101 578 713 948
MDR-TB, multidrug-resistant tuberculosis.
a Source: Global TB database (http://www.who.int/tb/country/data/download/en/).
b Data for high TB-burden countries only.underlying reasons require thorough evaluation. The fact that
some countries have performed well – Cambodia and Viet Nam
have consistently achieved treatment success in more than 70% of
cases6,7 – demonstrates the importance of sharing best practices
and learning from each other.
Yet another challenge is that PMDT will generate XDR-TB. The
risk can be minimized with ongoing surveillance of local drug
resistance proﬁles, optimization of standard treatment regimens,
and meticulous attention to all the programmatic factors outlined
above. The provision of treatment for XDR-TB, palliative care, and
infection control measures needs to be strengthened to address
this challenge. It reiterates the need for PMDT scale-up to be based
on a well-functioning DOTS programme, with proven readiness
and the necessary country commitment. If basic DOTS pro-
grammes are dysfunctional, then every effort must be made to
correct this in order to reduce the risk of multiplication of
resistance and protect future treatment options. Undesirable
channelling of resources from DOTS programmes may weaken the
base of PMDT. Suboptimal PMDT within a poorly functional DOTS
programme may pose more public health risk than beneﬁt.12,13
Other obstacles identiﬁed are limited human resources,
inadequate diagnostics, and misalignment of diagnostic and
treatment capacity, especially with the roll-out of the Xpert
MTB/RIF test in many countries. A particular challenge within the
Region has been the size and unregulated nature of the private
sector. The long-term sustainability of programmes has been
threatened by donor dependence. Unrealistic donor-driven targets
may have unintended consequences, such as fragmenting service
delivery and encouraging inaccurate reporting to save face. The
delicate balances between ambition, vision, reality, and feasibility,
together with the ability to measure progress and gaps, have to be
considered at all times.
6. Future role
The rGLC WPR has overseen major progress in PMDT scale-up
during its initial years. It has also generated greater awareness of
regional challenges and has encouraged local solutions to these
problems. Countries need continuous support, regular monitoring,
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expansion, and nationwide scale-up phases. Quick changes are
fraught with danger if the basic groundwork has not been
consolidated.
The rGLC WPR needs to ensure its own relevance and
sustainability into the future. Future activities aim to cover the
following priority areas: (1) providing strategic oversight and
advocacy to improve high-level political commitment, as evidenced
by action plans at different levels of the country as appropriate and
increased domestic funding; (2) maintenance of essential monitor-
ing, evaluation, and supervision activities, as well as providing a
platform for sharing experiences; (3) provision of technical support
and contextualized guidance, including assistance with the intro-
duction of new drugs and regimens; and (4) training and capacity
building, including basic operational research.
Regional initiatives should be dynamic and responsive to the
needs of member countries, but retain a focus on the priority areas
outlined. This requires close collaboration with global efforts and
ought to be a key component of the newly consolidated Global
Drug-resistant TB Initiative (GDI).14 Funding of rGLC WPR activities
depends on the Global Fund cost-sharing mechanism, with
contributions from the United States Agency for International
Development (USAID) and Japan. Secure funding into the future
will sustain and improve current support efforts.
Conﬂict of interest: This article is an expression of the views of
the Secretariat and members of the Western Paciﬁc Regional Green
Light Committee.
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